Helicobacter pylori colonises the gastric mucosa and is associated with various gastric diseases, including stomach cancer. At least 1 million new cases of stomach cancer cases are reported annually, and it is the fifth top cancer-killer in the world. Although H. pylori can be eradicated by a combination of antibiotics, the treatment success rate is declining due to the rise of antibiotic resistance. The same antibiotic combination must not be prescribed repeatedly. Susceptibility guided precision medicine is the most effective strategy to combat antibiotic resistant H. pylori cases. In addition, maintaining a stomach pH ≥6 during the antibiotic treatment is an important factor to increase cure rates. The new type of acid blocker, P-CABs, have shown promising results in H. pylori treatment. Natural products may suppress the H. pylori growth or relieve the symptoms but have not been successful in solving the root of the problem. New combination therapies show promise and the dream of 100% cure of the infection with minimal side effects from treatment seems achievable. The next decade will see combination therapies with newer acid blockers in widespread use at reasonable cost.

幽门螺杆菌定植在胃粘膜上，并与包括胃癌在内的各种胃病有关。每年至少报告一百万例胃癌新病例，它是世界第五大癌症杀手。尽管幽门螺杆菌可通过联合使用抗生素来根除，但由于抗生素耐药性的提高，治疗成功率正在下降。不得重复处方相同的抗生素组合。药敏指导的精密药物是对抗抗生素耐药的幽门螺杆菌病例的最有效策略。此外，在抗生素治疗过程中保持胃pH≥6是提高治愈率的重要因素。新型的酸阻滞剂P-CABs在幽门螺杆菌的治疗。天然产物可以抑制幽门螺杆菌的生长或缓解症状，但未能成功解决问题的根源。新的联合疗法显示出希望，并且实现100％治愈感染且副作用最小的梦想似乎是可以实现的。在接下来的十年中，将以合理的成本广泛使用带有新型酸阻滞剂的组合疗法。